MedTrace Logo

Apolipoprotein CIII Reduction Via Colchicine

NCT02083510 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2014-05-30

No results posted yet for this study

Summary

The aim of this trial will be to determine an effect-size for the administration of chronic low-dose colchicine in the reduction of serum levels of triglycerides (TG), very-low density lipoproteins (VLDL), and apolipoprotein CIII (apoCIII) in human subjects over a period of 4-6 weeks.

Conditions

  • Hypertriglyceridemia
  • Gout
  • Pericarditis

Interventions

DRUG

Colchicine

Sponsors & Collaborators

  • Scripps Translational Science Institute

    lead OTHER

Principal Investigators

  • Peter Schultz, PhD · Scripps Translational Science Institute

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02083510 on ClinicalTrials.gov